




Opus One 2013 & 2014 Inefficient Pricing Creates Opportunities

- **Opus One** is a joint-venture between **Robert Mondavi** and Bordeaux's **Baron Philippe de Rothschild** (of Château Mouton-Rothschild).
- Opus One has become a **major collectable wine** around the world, with excellent historical performance.
- Opus One is **not efficiently priced** by the market at the moment. Its Price / Score curve slopes downwards, with a low r^2 . This creates a buying opportunity in the **2013** and **2014** wines, which the graph shows to be significantly undervalued versus older vintages.
- **Opus One 2013** scores **100 points** from James Suckling, the first Opus One to receive a perfect score. Fair Value is around £2,000/6, giving **upside of over 27%**.
- **Opus One 2014** scores **97 points**. This is the second highest score achieved by Opus. Fair Value is around £1,775/6, offering a **return of 21%**.


How Fine Wine Prices are Supposed to Look

Fine Wine prices generally follow a smooth curve. The higher the critic score, the higher the price. Bordeaux's **Château Canon** illustrates the point. All the recent vintages of Canon are very close to the 'best fit' regression line (price against score), and the r^2 is 88% (which means the relationship is very strong).




Opus One Pricing is Not Yet Efficient ...

But Opus One pricing is all over the place. There is very little correlation (currently) between score and price.



We believe it is only a matter of time before the market prices Opus One efficiently. We have tried to calculate what that would mean for the 2013 and 2014 wines:



We predict that once the market settles the pricing will look more like the graphic above. In numeric terms, this means:

Wine (6x75cl)	Current Price	Fair Value	Upside	Score
Opus One 2014	£ 1,465	£ 1,775	21.2%	97 (JS)
Opus One 2013	£ 1,570	£ 2,000	27.4%	100 (JS)

Opus One 2013:

- Opus One 2013 scores **100 points** from James Suckling, the first Opus One ever to receive a perfect score.
- To be consistent with other fine wine Price / Score curves, we estimate that Opus One 2013 Fair Value to be **not less than £2,000/6**.
- **Upside potential is almost 30%**, from current offer price of £1,570.

Opus One 2014:

- Opus One 2014 scores **97 points** from James Suckling, the joint second highest score ever.
- This wine should also benefit as the Opus One **pricing curve gets more efficient**.
- We anticipate this wine correcting upwards to around **£1,775/6**, giving **upside of over 21%**.

IMPORTANT NOTICE

This report has been issued or approved for issue by an entity forming part of Cru (as defined below) and has been forwarded to you solely for your information and should not be considered as an offer or solicitation of an offer to sell, buy or subscribe to any securities or any derivative instrument or any other rights pertaining thereto ("financial instruments"). This report is intended for use by professional or business investors only. This report may not be reproduced without the consent of Cru.

The information and opinions expressed in this report have been compiled from sources believed to be reliable, but, neither Cru, nor any of its directors, officers, or employees accepts liability from any loss arising from the use hereof or makes any representations as to its accuracy and completeness. Any opinions, forecasts or estimates herein constitute a judgement as at the date of this report. There can be no assurance that future results or events will be consistent with any such opinions, forecasts or estimates. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied is made regarding future performance. This information is subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed and it may not contain all material information concerning the product or products mentioned. Cru is not agreeing to nor is it required to update the opinions, forecasts or estimates contained herein.

The value of any products mentioned in this report can fall as well as rise. Foreign currency denominated products are subject to fluctuations in exchange rates that may have a positive or adverse effect on the value, price or income of such products.

This report does not have regard to the specific instrument objectives, financial situation and the particular needs of any specific person who may receive this report. Investors should seek financial advice regarding the appropriateness of investing in any products or investment strategies discussed in this report.

Cru (or its directors, officers or employees) may, to the extent permitted by law, own or have a position in the products of any company or related company or products referred to herein, and may add to or dispose of any such position or may make a market or act as a principal in any transaction in such products. Directors of Cru may also be directors of any of the companies mentioned in this report. Cru (or its directors, officers or employees) may, to the extent permitted by law, act upon or use the information or opinions presented herein, or research or analysis on which they are based prior to the material being published. Cru may have issued other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods of the analysts who prepared them.

For the purposes of this disclaimer, "Cru" shall mean: (i) Cru London Limited; (ii) Cru Asia Limited and (iii) from time to time, in relation to Cru London Limited and/or Cru Asia Limited, the ultimate holding company of that entity, a subsidiary (or a subsidiary of a subsidiary) of that entity, a holding company of that entity or any other subsidiary of that holding company, and any affiliated entity of any such entities.

This publication is confidential for the information of the addressee only and may not be reproduced in whole or in part, copies circulated, or disclosed to another party, without the prior written consent of an entity within Cru. Products referred to in this research report may not be eligible for sale in those jurisdictions where an entity within Cru is not authorised or permitted by local law to do so. In particular, Cru does not allow the redistribution of this report to non-professional investors or persons outside the jurisdictions referred to above and Cru cannot be held responsible in any way for third parties who effect such redistribution or recipients thereof. © 2017.